Copyright
©The Author(s) 2021.
World J Gastroenterol. Nov 21, 2021; 27(43): 7572-7581
Published online Nov 21, 2021. doi: 10.3748/wjg.v27.i43.7572
Published online Nov 21, 2021. doi: 10.3748/wjg.v27.i43.7572
Ulcerative colitis-comparison | Ulcerative colitis-difference achieved (Group 1–Placebo) | Ulcerative colitis-Minimum sample size needed based on data | Crohn’s disease-comparison | Crohn’s disease-difference achieved (Group 1–Placebo) | Crohn’s disease-Minimum sample size needed based on data |
Induction studies | |||||
Outcome–clinical remission | Outcome–clinical remission | ||||
Vedolizumab vs Placebo | 14.8% | 190 | Glutamine-enriched diet vs Placebo | -11.1 | 634 |
Azathioprine vs Placebo | -3.6% | NA | |||
6-MP vs Placebo | 5% | NA | |||
Fecal Transplant vs Control | 20.3% | 150 | 6-MP vs Placebo | 5% | NA |
Budesonide vs Placebo | 6.5% | NA | Interventional diet vs Control diet | 20.9% | 160 |
Type 1 IFNs vs Placebo | 5.9% | NA | Elemental diet vs Non elemental diet | 1.6% | NA |
Etrolizumab vs Placebo | 13.4% | 140 | N6/N9 rich feeds vs non N6/N9 rich food | -1.1% | NA |
Low dose naltrexone vs Placebo | 9% | NA | |||
5-ASA vs Placebo | 11.8% | 422 | GM-CSF vs Placebo | 7.8% | NA |
Outcome–endoscopic remission | Brakinumab vs Placebo | 8.5% | NA | ||
Vedolizumab vs Placebo | 37.7% | 182 | Ustekinumab vs Placebo | 8.6% | NA |
Natalizumab vs Placebo | 14.8% | 310 | |||
Fecal Transplant vs Control | 26.4% | 160 | Methotrexate vs Placebo | -14.8% | 350 |
Budesonide vs Placebo | 13.9% | NA | Antibiotics vs Placebo | 10% | 780 |
Methotrexate vs Placebo | 46.7% | NA | Outcome–endoscopic remission | ||
Etrolizumab vs Placebo | 7.7% | NA | Low dose naltrexone vs Placebo | 22.2% | 60 |
5-ASA vs Placebo | 53.7% | 306 | |||
Maintenance studies | |||||
Outcome–clinical relapse | Outcome–clinical relapse | ||||
5-ASA vs Placebo | -16.4% | 290 | 5-ASA vs Placebo, medically induced | 3.1% | NA |
Vedolizumab vs Placebo | -27.4 | 84 | 5-ASA vs Placebo, surgically induced | -5.4% | NA |
Interventional diet vs Control diet | -3.6% | NA | Anti-TB vs Placebo | -23% | 130 |
Probiotics vs Control | -16.7 | 154 | Azathioprine vs Placebo, medically induced | -9.9% | NA |
Azathioprine vs Placebo | -22.4 | 154 | Azathioprine vs Placebo, surgically induced | -17.3% | 254 |
Methotrexate vs Placebo | 19.9% | 194 | 6-MP vs Placebo, surgically induced | -10.9% | 646 |
Rectal 5-ASA vs Placebo | -29% | 90 | Omega -3 fatty acids diet vs Control diet | -8.5% | NA |
Curcumin vs Placebo | -9.6% | NA | Elemental diet vs No supplemets | -29.4% | 88 |
Outcome–endoscopic relapse | Interventional diet vs Control diet | -2.5% | NA | ||
Vedolizumab vs Placebo | -34 | 60 | Antibiotics vs Placebo | -14.6% | 360 |
Methotrexate vs Placebo | -24.2% | 128 | |||
5-ASA vs Placebo | -16.4% | 290 | Methotrexate vs Placebo | -24.2% | 128 |
Outcome–endoscopic relapse | |||||
5-ASA vs Placebo | 2.7% | NA | |||
Azathioprine vs Placebo | -23% | 130 | |||
6-MP vs Placebo | -3.8% | NA | |||
Antibiotics vs Placebo | 6.6% | NA | |||
Induction studies | |||||
Outcome–clinical remission | Outcome–clinical remission | ||||
Vedolizumab vs Placebo | 14.8% | 190 | Glutamine-enriched diet vs Placebo | -11.1 | 634 |
Azathioprine vs Placebo | -3.6% | NA | |||
6-MP vs Placebo | 5% | NA | |||
Fecal Transplant vs Control | 20.3% | 150 | 6-MP vs Placebo | 5% | NA |
Budesonide vs Placebo | 6.5% | NA | Interventional diet vs Control diet | 20.9% | 160 |
Type 1 IFNs vs Placebo | 5.9% | NA | Elemental diet vs Non elemental diet | 1.6% | NA |
Etrolizumab vs Placebo | 13.4% | 140 | N6/N9 rich feeds vs non N6/N9 rich food | -1.1% | NA |
Low dose naltrexone vs Placebo | 9% | NA | |||
5-ASA vs Placebo | 11.8% | 422 | GM-CSF vs Placebo | 7.8% | NA |
Outcome–endoscopic remission | Brakinumab vs Placebo | 8.5% | NA | ||
Vedolizumab vs Placebo | 37.7% | 182 | Ustekinumab vs Placebo | 8.6% | NA |
Natalizumab vs Placebo | 14.8% | 310 | |||
Fecal Transplant vs Control | 26.4% | 160 | Methotrexate vs Placebo | -14.8% | 350 |
Budesonide vs Placebo | 13.9% | NA | Antibiotics vs Placebo | 10% | 780 |
Methotrexate vs Placebo | 46.7% | NA | Outcome–endoscopic remission | ||
Etrolizumab vs Placebo | 7.7% | NA | Low dose naltrexone vs Placebo | 22.2% | 60 |
5-ASA vs Placebo | 53.7% | 306 | |||
Maintenance studies | |||||
Outcome–clinical relapse | Outcome–clinical relapse | ||||
5-ASA vs Placebo | -16.4% | 290 | 5-ASA vs Placebo, medically induced | 3.1% | NA |
Vedolizumab vs Placebo | -27.4 | 84 | 5-ASA vs Placebo, surgically induced | -5.4% | NA |
Interventional diet vs Control diet | -3.6% | NA | Anti-TB vs Placebo | -23% | 130 |
Probiotics vs Control | -16.7 | 154 | Azathioprine vs Placebo, medically induced | -9.9% | NA |
Azathioprine vs Placebo | -22.4 | 154 | Azathioprine vs Placebo, surgically induced | -17.3% | 254 |
Methotrexate vs Placebo | 19.9% | 194 | 6-MP vs Placebo, surgically induced | -10.9% | 646 |
Rectal 5-ASA vs Placebo | -29% | 90 | Omega -3 fatty acids diet vs Control diet | -8.5% | NA |
Curcumin vs Placebo | -9.6% | NA | Elemental diet vs No supplemets | -29.4% | 88 |
Outcome–endoscopic relapse | Interventional diet vs Control diet | -2.5% | NA | ||
Vedolizumab vs Placebo | -34 | 60 | Antibiotics vs Placebo | -14.6% | 360 |
Methotrexate vs Placebo | -24.2% | 128 | |||
5-ASA vs Placebo | -16.4% | 290 | Methotrexate vs Placebo | -24.2% | 128 |
Outcome–endoscopic relapse | |||||
5-ASA vs Placebo | 2.7% | NA | |||
Azathioprine vs Placebo | -23% | 130 | |||
6-MP vs Placebo | -3.8% | NA | |||
Antibiotics vs Placebo | 6.6% | NA |
- Citation: Gordon M, Lakunina S, Sinopoulou V, Akobeng A. Minimum sample size estimates for trials in inflammatory bowel disease: A systematic review of a support resource. World J Gastroenterol 2021; 27(43): 7572-7581
- URL: https://www.wjgnet.com/1007-9327/full/v27/i43/7572.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i43.7572